1. FDA Committee Votes 6-6 on Durect's Non-Opioid Pain Drug — Eli Lilly targets quarterly deals of $1 billion-$5 billion in 2020 — Novo Nordisk's Ozempic wins FDA label boost with CV indication — See more on our front page news TRY TWO WEEKS OF OUR EMAIL NEWS HEADLINES FOR FREE
    Dismiss Notice
  2. Think you have witnessed fraud?Ask a Whistleblower Attorney -- a chance to discuss whistleblower-related legal issues with practicing whistleblower attorneys.
    Dismiss Notice

Surgeon commission ?

Discussion in 'Medacta' started by anonymous, Aug 9, 2016 at 8:11 PM.

  1. anonymous

    anonymous Guest

    Heard they are offering commission to surgeon who use the product anyone seen this?
     
  2. anonymous

    anonymous Guest

     
  3. anonymous

    anonymous Guest

    Why else would you use an unproven move expensive system with no clinical advantages?
     
  4. anonymous

    anonymous Guest

    Medacta has got great products. The 3rd most impanted cementless stem on the Australian hip registry is from Medacta.
    Not bad for a relative new company.
     
  5. anonymous

    anonymous Guest

    They are great at imitation copies every product!
    And then sweeten deal for surgeons with "consultancy"
     
  6. anonymous

    anonymous Guest

    So you can't sell so any company that takes business does it by violating compliance guidelines. What a looser.
     
  7. anonymous

    anonymous Guest

    With big contracts squeezing out most minor players in the industry, the only time I see Medacta is when surgeons are getting something in return. How is it that when you have to be at 3k for a knee, Medacta is priced at 6 and doing biz? Because doc is in tight with rep who "keeps" his toys parked at docs house. "Here's the keys for the dirt bike doc, can you 'store' it for me? Thanks."
     
  8. anonymous

    anonymous Guest

    Medacta offers surgeons more freedom by allowing consultancy to be taken out of the hospital to surgery centers. Product costs more because of single use instruments allow for quick turnover which actually saves surgery centers money. It's the direction recon surgeries are going and Medacta just had enough foresight to cut into that market.